Загрузка...
Reduced tyrosine kinase inhibitor dose is predicted to be as effective as standard dose in chronic myeloid leukemia: a simulation study based on phase III trial data
Continuing tyrosine kinase inhibitor (TKI)-mediated targeting of the BCR-ABL1 oncoprotein is the standard therapy for chronic myeloid leukemia (CML) and allows for a sustained disease control in the majority of patients. While therapy cessation for patients appeared as a safe option for about half o...
Сохранить в:
| Опубликовано в: : | Haematologica |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Ferrata Storti Foundation
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6278983/ https://ncbi.nlm.nih.gov/pubmed/29954936 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2018.194522 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|